- Your cart is empty
- Continue Shopping
Product Description
Lenvima contains Lenvatinib which belongs to the group of medicines called Antineoplastic agents. It is used to treat differentiated thyroid cancer (DTC), advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and advanced endometrial carcinoma (EC).
It belongs to the group of medicines called tyrosine kinase inhibitors, works by inhibiting the action of receptor tyrosine kinases (proteins responsible for development of new blood vessels) which leads to poor oxygen and nutrient supply to the cancer cell resulting in its destruction thus treating cancer in affected individuals.
Inform the doctor if you have Inform the doctor if you have high blood pressure, aneurysm (enlargement and weakening of blood vessel wall), history of blood clots in your arteries, heart diseases (such as congestive heart failure, heart attack), kidney diseases (such as mild/moderate/severe renal impairment), and/or liver diseases (such as mild/moderate/severe hepatic impairment).
Inform the doctor about all your medical conditions, prescription and non-prescription drugs, vitamin supplements, herbal medications, since Lenvima can interact with them. Lenvima can cause an allergic reaction in some patients therefore it is necessary to read the complete composition list and consult the doctor in case of any ingredient that induces allergies. This medicine may make your skin more sensitive to sun, so it is better to use sunscreen and protective clothing when outdoors.
Consult the doctor if you are planning, on a pregnancy or breastfeeding.
It is advisable to avoid driving and operating heavy machinery during the course of Lenvima.
Indications of LENVIMA Capsule
Lenvima is indicated for the treatment of differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing; advanced renal cell carcinoma (RCC), a type of kidney cancer; hepatocellular carcinoma (HCC), a type of liver cancer when it cannot be removed by surgery and advanced endometrial carcinoma (EC), a type of uterine cancer in adults in whom the cancer has spread and cannot be removed by surgery/radiation treatment.
Therapeutic Effects of LENVIMA Capsule
Lenvima contains Lenvatinib which belongs to the group of medicines called Antineoplastic agents. It works by inhibiting the action of receptor tyrosine kinases (proteins responsible for development of new blood vessels) which leads to poor oxygen and nutrient supply to the cancer cell resulting in its destruction thus treating cancer in affected individuals.
Directions for Use
Lenvima Capsule should be taken with food preferably at the same time each day. The capsule should be swallowed whole with water and should not be crushed, chewed, or opened. The dosage and duration of treatment will depend on the individual’s condition and response to the medication and should be determined by the doctor.
Your doctor will decide the dose and frequency of administration based on your health condition.
A trained healthcare doctor will administer Lenvima. So, do not self-administer.
Storage
Lenvima Capsule should be stored below 30°C temperature at room temperature.Do no freeze.
If you are traveling, carefully follow all patient instructions for storing your medicine during travel. Avoid extreme heat or cold.
Keep in the original container to protect from light and moisture.
Keep Lenvima Capsule out of sight and reach of children.
Common:
- High/low blood pressure
- Muscle pain, feeling unwell with body pain
- Dizziness, tiredness, weakness
- Bleeding (most commonly nose bleeds)
- Signs of blood clots in the lungs such as difficulty breathing, chest pain
- Signs of decreased red blood cells such as weakness, dizziness, chest pain
- Pounding/racing heartbeat
- Reduced appetite/weight loss
- Nausea, vomiting, constipation, stomach pain, diarrhoea, indigestion
- Hoarse Voice
- Swelling of the legs
- Rash
- Dry/sore/inflamed mouth
- Loss of proper taste sensation
- Joint pain, back pain
- Headache, hair loss
- Difficulty in sleeping
- Signs of palmar-plantar erythrodysesthesia (hand-foot syndrome) such as swelling, redness and soreness of skin on hands and feet
- Signs of underactive thyroid such as weight gain, tiredness, constipation, dry skin, feeling cold
- Signs of decreased count of white blood cells such as body aches, chills, fever and headaches.
- Signs of reduced platelets count such as bruising and delayed wound healing
- Signs of increased amylase and lipase levels in blood such as ulcer, pancreatitis (inflammation of pancreas)
- Dehydration
- Dry skin, itching and thickening of the skin
- Feeling bloated or having excess wind
- Signs of liver failure such as dizziness, loss of sleep, confusion, decreased concentration, loss of consciousness
- Inflammation of the gallbladder
- Signs of stroke such as feeling numb or weak on one side of your body, severe headache, seizure, confusion, difficulty talking, vision changes or feeling dizzy
- Anal fistula (a small channel between the anus and surrounding skin)
- Signs of urinary infections such as increased frequency in urination and pain in passing urine
Serious:
- Painful infection and irritation near the anus
- Signs of heart problems such as chest pain/pressure, pain in arms, back, neck/ jaw, shortness of breath, rapid/ irregular heart rate, coughing, bluish color of lips/fingers, and feeling very tired
- Mini stroke
- Damage to the liver
- Signs of splenic infarction (condition marked by poor blood supply to spleen) such as chills, fever, nausea and pain in the upper left part of the abdomen
- Signs of inflammation of the pancreas such as upper abdominal pain, fever, fast pulse
- Problems in wound healing
- Osteonecrosis (damage to the bones in jaw)
Tell a doctor or nurse straight away, if you notice any of the side effects above.
Contraindications
Lenvima is contraindicated in patients with a known hypersensitivity to Lenvima or any of the excipients.
Drug Interactions
Lenvima might interact with other medicines. Therefore, it is recommended to inform your doctor about all the prescriptions you have.
Safety Advices for LENVIMA Capsule
Consult Your Doctor
It is unknown whether Lenvima Capsule interacts with alcohol. It is best to avoid alcohol or limit your alcohol consumption while taking any medication and consult your doctor.
Unsafe
Lenvima is not recommended for use in pregnancy as it may cause embryo-fetal toxicity and harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before taking Lenvima Capsule.
Unsafe
Avoid breastfeeding your baby while on the treatment with Lenvima, as it may pass through breast milk. Consult your doctor if you are breastfeeding before taking this medication.
Unsafe
Lenvima may cause dizziness and fatigue in some patients. Therefore, avoid driving or operating machines that require mental concentration until you are not alert.
Caution
If you have any lung-related symptoms, such as cough, shortness of breath, and difficulty breathing, consult your doctor. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Caution
If you have a pre-existing or a history of liver problems, consult your doctor before taking this medicine. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Caution
Lenvima is known to cause kidney impairment. Hence, if you have a pre-existing or a history of kidney diseases, inform your doctor before taking Lenvima. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Unsafe
Lenvima is not recommended for children below 18 years as the safety and effectiveness were not established. Consult your doctor before taking the medicine.
- 1. Lenvima (Lenvatinib Capsules); 2019. [Accessed 05 Feb. 2020] (online) Available from
- 2. Lenvatinib [Prescribing Information]. Woodcliff Lake, NJ: Eisai Inc.; 2019. [Accessed 05 Feb. 2020] (online) Available from
- 3. Eisai Manufacturing Limited. Electronic Medicines Compendium (EMC). [Revised in November 2021] [Accessed 16th August 2022] https://www.medicines.org.uk/emc/product/6840/pil
- 4. Eisai GmbH. European Medicines Agency (EMA). [Revised in May 2015] [Accessed 16th August 2022] https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_en.pdf
Disclaimer
While we strive to provide complete, accurate, and expert-reviewed content on our ‘Platform’, we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user’s risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship. All Trademarks, Brands and Service marks that appear on this website belong to their respective owner.
